- Home
- ECBK vs CCCC Comparison
ECBK vs CCCC Comparison
Compare ECBK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- CCCC
- Stock Information
- Founded
- ECBK 1919
- CCCC 2015
- Country
- ECBK United States
- CCCC United States
- Employees
- ECBK N/A
- CCCC N/A
- Industry
- ECBK Banks
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- CCCC Health Care
- Exchange
- ECBK Nasdaq
- CCCC Nasdaq
- Market Cap
- ECBK 151.0M
- CCCC 175.1M
- IPO Year
- ECBK N/A
- CCCC 2020
- Fundamental
- Price
- ECBK $15.48
- CCCC $2.22
- Analyst Decision
- ECBK
- CCCC Strong Buy
- Analyst Count
- ECBK 0
- CCCC 4
- Target Price
- ECBK N/A
- CCCC $8.50
- AVG Volume (30 Days)
- ECBK 11.6K
- CCCC 2.4M
- Earning Date
- ECBK 10-23-2025
- CCCC 10-30-2025
- Dividend Yield
- ECBK N/A
- CCCC N/A
- EPS Growth
- ECBK 52.06
- CCCC N/A
- EPS
- ECBK 0.64
- CCCC N/A
- Revenue
- ECBK $27,795,000.00
- CCCC $34,240,000.00
- Revenue This Year
- ECBK N/A
- CCCC N/A
- Revenue Next Year
- ECBK N/A
- CCCC N/A
- P/E Ratio
- ECBK $24.51
- CCCC N/A
- Revenue Growth
- ECBK 12.29
- CCCC 16.55
- 52 Week Low
- ECBK $12.56
- CCCC $1.09
- 52 Week High
- ECBK $17.33
- CCCC $7.14
- Technical
- Relative Strength Index (RSI)
- ECBK 38.36
- CCCC 40.78
- Support Level
- ECBK $15.66
- CCCC $2.09
- Resistance Level
- ECBK $16.47
- CCCC $2.38
- Average True Range (ATR)
- ECBK 0.22
- CCCC 0.23
- MACD
- ECBK -0.04
- CCCC -0.06
- Stochastic Oscillator
- ECBK 14.59
- CCCC 7.05
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.